innovation Rodrigo Iturralde, general manager of Randall, walks us through the new plans of the company after a year of difficult yet enriching challenges and the ambitious goals set with an innovative strategy. Today generics represent 85 percent of the market in terms of volume, making Mexico one of the biggest…
transparency In 2014 the National Academy of Medicine celebrated its 150th anniversary. The president of the renowned medical institution discusses the recent activities of the academy, the importance of increasing transparency in the relationship between the pharmaceutical industry, healthcare institutions and physicians. This year the National Academy of Medicine celebrates its…
biotech Francisco Molinari, CEO of Argentina’s most sophisticated biotech group discusses Argentina’s competitiveness in the global biosimilar market, the current constraints limiting innovation in Argentina, and his company’s recent transition from an API producer to a fully integrated biosimilar developer and manufacturer. How would you describe the current state of the…
innovation The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current scenario for local companies and outlines his ambitions for making Korea a global hub for innovation. Since we met…
commercialization Founder of Promedon Marcelo Olmedo discusses innovation in Cordoba, and the birth and success of Promedon, a flagship company of the region. How do you see the importance of the relationships between the private sector and the universities as being a key to success in the region? In order…
innovation Mexico is one of GSK’s growth engines in Latin America. The VP and general manager for Mexico discusses how the country is increasingly playing a strategic role for the company to get new healthcare products faster to the market by leveraging local R&D. Besides Asia Pacific and Japan,…
innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients. You have had…
Boston Consulting Group The managing director of Boston Consulting Group Malaysia discusses the gap between public and private healthcare in the country, and what can be done to bridge it. What appears to be a focus for many companies now is bridging the gap between the private healthcare sector and the public…
Frost & Sullivan Rhenu Bhuller provides insight into Malaysia’s healthcare industry positioning in the Southeast Asian region and the ability to provide affordable quality healthcare in a country that is naturally diverse as an important competitive advantage. The pharmaceutical sector has been the fastest growing industry in Malaysia between 2000 and 2009,…
Biotech The CEO of Venter Pharma explains the challenges of bringing a diagnostic drug to the market, and how they hope to leverage the science behind their product, LacTEST, in various new forms and indications. Before you came on board at Venter Pharma, the research for your product LacTEST was…
innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success. What have been some of the most important changes made…
innovation Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of the world for disruptive and incremental innovation. What are the current trends in Korea’s pharmaceutical industry? The global market…
See our Cookie Privacy Policy Here